Navigation Links
Roche, Baylor Research Institute Partner in Human Immunology Research
Date:12/3/2010

DALLAS, Dec. 3, 2010 /PRNewswire-USNewswire/ -- Baylor Research Institute (BRI), the research arm of Baylor Health Care System, announced that it has formed a three-year partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop programs emerging from the human immunology platforms developed at the Baylor Institute for Immunology Research (BIIR), a component of BRI.

These programs will leverage BIIR's leading position in human immunology with particular focus on cancer vaccines, auto-immune disease diagnostics and treatment, proprietary platforms in biosignature and antibody development, with a view at identifying new leads that could be in-licensed by Roche. A Joint Research Committee will determine the most promising projects in that context, to be funded by Roche over a three-year period.

BRI will retain sole responsibility for programs outside the jointly developed projects.

"The worldwide reputation in human immunology established by Jacques Banchereau  and his team over the years and the uniqueness of some of their programs clearly fit Roche's strategic discovery plans for novel approaches in diagnosing and treating diseases where our company wants to expand its franchise," said Jean-Jacques Garaud, MD., Head of Roche Pharma Research & Early Development (pRED).

Banchereau, formerly the director at BIIR, is senior vice president, head of the Inflammation and Virology Discovery and Translational Areas and chief scientific officer at Roche.

"The partnership with a world leader such as Roche will help tremendously in accelerating the translation of our leading innovative science in human immunology, into diagnostics and treatments that will benefit patients worldwide," said Michael A.E. Ramsay, MD., FRCA, president of BRI.

About BRI: Established in 1984 in Dallas, Texas, Baylor Research Institute (BRI) promotes and supports research to bring innovative treatments from the laboratory workbench to the patient bedside. To achieve this bench-to-bedside concept, BRI focuses on basic science, clinical trials, healthcare effectiveness and quality of care research. Today, BRI is conducting more than 800 active research protocols with 250 research investigators, spanning more than 20 medical specialties, and has research and development projects in areas ranging from human immunology and orphan metabolic diseases to diabetes, cardio-vascular disease and many other unmet medical needs.

www.baylorhealth.edu/Research/FOR MORE INFORMATION, CONTACT: Kristine Hughes Communications Coordinator 214-820-7556 (O) kristine.hughes@baylorhealth.edu
'/>"/>

SOURCE BAYLOR RESEARCH INSTITUTE
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Ambry Genetics Announces the Addition of Array CGH Services Through Partnership With Baylor College of Medicine
2. Leading LASIK Laser Eye Cataract Surgery Experts of Baylor Vision in Houston Join Trusted LASIK Surgeons Directory
3. NIH Funds $1M Research at Quest Product Development and University of Colorado for New Digitally-Controlled Endoscopes
4. Canopus Biopharma and Leading Chinese Researcher Team Up to Treat Avian Influenza, to Prevent Possible Pandemic
5. Association of Clinical Research Organizations (ACRO) Welcomes Clinilabs and RPS as New Members
6. Melior Enters Research Collaboration with AstraZeneca
7. UC Riverside researcher develops novel method to grow human embryonic stem cells
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
9. Cryo-Cell International and EndGenitor Technologies Announce Research Collaboration
10. US Oncology Appoints Stephen Smith Vice President/General Manager Research and Personalized Science Services
11. Cyntellect to Collaborate With the Burnham Institute for Medical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a major research ... GSK to generate genetic sequence data from the 500,000 volunteer ... researchers to gain valuable insights to support advances in the ... and life threatening diseases. ... Genetic evidence has revolutionized scientific discovery ...
(Date:3/22/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... ), a clinical-stage pharmaceutical company focused ... announced today that Dr. Miriam Kidron , ... titled, "Oral Insulin for Diabetes Treatment: Bypassing the ... and Peptide Therapeutics (OPT) Boston Conference in ...
(Date:3/22/2017)... , March 22, 2017   Boston Biomedical , ... therapeutics designed to target cancer stemness pathways, today announced ... Andrews as Chief Executive Officer, effective April 24, ... Chiang J. Li , M.D., FACP, who has led ... ago. Under his leadership, Boston Biomedical has grown from ...
(Date:3/22/2017)... ... ... Benchworks CEO Thad L. Bench Sr. will participate in the ... San Diego. The event is a gathering of executive leadership from companies in the ... Meyer will also participate in the forum. Participants will discuss the future of the ...
Breaking Biology Technology:
(Date:3/2/2017)... -- Summary This report provides all the ... its partnering interests and activities since 2010. Download ... Partnering Deals and Alliance since 2010 report provides an ... the world,s leading life sciences companies. On ... inclusion of the most up to date deal and ...
(Date:2/28/2017)... ANGELES , Feb. 28, 2017   Acuant ... verification software globally, announces significant enhancements to new and ... May 2016. New products include mobile and desktop Acuant ... DocX TM - a real time manual review ... core idScanĀ® technology provides the fastest and most accurate ...
(Date:2/26/2017)... Feb. 25, 2017  Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring, announces ... Reentry. "Too often, too many offenders ... county jails are trying to tackle this ongoing ... friends and family members. While significant steps are underway, ...
Breaking Biology News(10 mins):